**Abstract**

***Background:*** Sleep disturbances is a key symptom of depression and recently sleep disturbances have been suggested as a new area to optimize treatment in depression.

This study aims to investigate possible implications for abnormalities in orexin, a neuropeptide important in controlling sleep and arousal, in depression. Orexin is produced in the hypothalamus and projected throughout the brain innervating a number of structures important in depression. Orexin also controls a number of other physiological processes including cognitive processes, stress response and feeding, all of which are affected during depression in humans and disturbed in a number of depressive-like animal models.

***Methods:*** Using real-time qPCR and Western blotting optimal sampling time is determined by an initial assessment of the diurnal variation of orexin expression. Differences in the expression of orexin and its cognate receptors are investigated in the hypothalamus, the hippocampus, and the prefrontal cortex of two rat models of depression: the Flinders Sensitive Line (FSL) and the Chronic Mild Stress (CMS) model. Behavioural and molecular response to treatment with a conventional antidepressant, an orexin receptor antagonist, and of orexin-A itself will be addressed in the FSL rats. In addition we will include exercise as a non-invasive treatment, which has shown positive effects on both sleep and depression in human subjects. In parallel studies, we are investigating possible effects of the sleep inducing agent isoflurane on the orexinergic system.

***Preliminary results:*** Real-time qPCR analysis showed increased expression of the *orexin-1 receptor* (40%) and the *orexin-2 receptor* (39%) in the prefrontal cortex of FSL rats compared to its control strain, the Flinders Resistant Line (FRL) rat.

***Perspectives:*** This study may provide a platform for screening of drugs with positive effects on both sleep and depressive symptoms; thus the project provides perspectives for the development of novel strategies for improving treatment of depression.
